CCL19 Recombinant Monoclonal Antibody

說明書

中文名稱：

CCL19重組抗體
貨號(hào)：

CSB-RA859522A0HU
規(guī)格：

￥1320
圖片：
IHC image of CSB-RA859522A0HU diluted at 1:155 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

IHC image of CSB-RA859522A0HU diluted at 1:155 and staining in paraffin-embedded human appendix tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品描述：

CCL19重組單克隆抗體（產(chǎn)品編號(hào)CSB-RA859522A0HU）是一款高特異性科研工具，靶向趨化因子CCL19（又稱MIP-3β/ELC），該分子作為CCR7受體配體，在淋巴細(xì)胞歸巢、次級(jí)淋巴器官形成及免疫應(yīng)答調(diào)節(jié)中發(fā)揮關(guān)鍵作用，與腫瘤微環(huán)境調(diào)控、自身免疫性疾病及慢性炎癥過程密切相關(guān)。本抗體經(jīng)ELISA和免疫組化（IHC）雙重實(shí)驗(yàn)平臺(tái)嚴(yán)格驗(yàn)證，在IHC應(yīng)用中推薦使用1:50-1:200稀釋比例，可精準(zhǔn)識(shí)別石蠟包埋或冰凍組織樣本中的CCL19蛋白表達(dá)，呈現(xiàn)清晰的亞細(xì)胞定位信號(hào)，且無交叉反應(yīng)性。適用于研究CCL19在免疫細(xì)胞遷移、腫瘤免疫逃逸、炎癥性疾病機(jī)制中的功能，例如分析淋巴結(jié)、腸道相關(guān)淋巴組織或腫瘤浸潤(rùn)區(qū)域的趨化因子分布模式，或探索其在類風(fēng)濕性關(guān)節(jié)炎、炎癥性腸病等病理模型中的動(dòng)態(tài)變化。該產(chǎn)品為科研人員提供穩(wěn)定可靠的檢測(cè)方案，助力免疫微環(huán)境基礎(chǔ)研究與藥物靶點(diǎn)開發(fā)，所有應(yīng)用僅限于體外實(shí)驗(yàn)及科學(xué)研究領(lǐng)域。
Uniprot No.：

Q99731
基因名：

CCL19
別名：

Beta chemokine exodus 3 antibody; Beta-chemokine exodus-3 antibody; C C chemokine ligand 19 antibody; C-C motif chemokine 19 antibody; CC chemokine ligand 19 antibody; CCL 19 antibody; CCL19 antibody; CCL19_HUMAN antibody; Chemokine (C C motif) ligand 19 antibody; Chemokine (CC motif) ligand 19 antibody; Chemokine C C Motif Ligand 19 antibody; Chemokine CC Motif Ligand 19 antibody; CK beta 11 antibody; CK beta-11 antibody; CKb 11 antibody; CKb11 antibody; EBI 1 ligand chemokine antibody; EBI1 ligand chemokine antibody; ELC antibody; Epstein-Barr virus-induced molecule 1 ligand chemokine antibody; Exodus 3 antibody; Exodus3 antibody; Macrophage inflammatory protein 3 beta antibody; MGC34433 antibody; MIP 3 beta antibody; MIP 3B antibody; MIP-3-beta antibody; MIP-3b antibody; MIP3 beta antibody; MIP3B antibody; OTTHUMP00000000531 antibody; SCYA 19 antibody; SCYA19 antibody; Small inducible cytokine A19 antibody; Small inducible cytokine subfamily A (Cys Cys) member 1 antibody; Small-inducible cytokine A19 antibody
反應(yīng)種屬：

Human
免疫原：

A synthesized peptide derived from human CCL19
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號(hào)：

3A12
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

May play a role not only in inflammatory and immunological responses but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. Binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4.
基因功能參考文獻(xiàn)：
1. these data indicate CCL19/CCR7 contributes to proliferation and invasion of ESCs, which are conducive to the pathogenesis of endometriosis through activating PI3K/Akt pathway PMID: 28856757
2. The research findings demonstrate for the first time that the chemokines CCL19, CCL21 and CCR7 play important roles in bone destruction by increasing osteoclast migration and resorption activity, and that has been linked to rheumatoid arthritis pathogenesis. PMID: 28729639
3. breast cancers-derived soluble factors increase the migration of DCs toward CCL19. PMID: 27451948
4. The migratory index to the CCR7 ligands, CCL19 and CCL21, was higher in T-cells from donors whose recipients will develop GvHD. PMID: 28112745
5. Study confirmes that CCL19 induces the invasion and migration of breast cancer cells through the expression of markers of epithelial-mesenchymal transition. PMID: 28378417
6. findings connect NOTCH1, DUSP22, and CCL19-driven chemotaxis within a single functional network, suggesting that modulation of the homing process may provide a relevant contribution to the unfavorable prognosis associated with NOTCH1 mutations in CLL. PMID: 28017968
7. Deletion of this extended C-terminus reduces CCL21's affinity for heparin and transferring the CCL21 C-terminus to CCL19 enhances heparin binding mainly through non-specific, electrostatic interactions PMID: 27338641
8. CCL19 is significantly overexpressed in patients with unstable carotid atherosclerotic plaques and may be a possible novel biomarker for identifying high-risk patients in whom more urgent intervention may be indicated. PMID: 27498092
9. CrkL regulates CCL19 and CCR7-induced epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinoma patients. PMID: 25636509
10. The solution structure of CCL19 is reported. It contains a canonical chemokine domain. Chemical shift mapping shows the N-termini of PSGL-1 and CCR7 have overlapping binding sites for CCL19 and binding is competitive. PMID: 26115234
11. Our findings serve to elucidate the molecular mechanisms underlying the resistin induction of CCL19 expression in ECs and the shear-stress protection against this induction. PMID: 25656506
12. The mRNA levels of CCL19/CCL21 in ankylosing spondylitis hip ligament were significantly higher than in osteoarthritis ligament. PMID: 25260647
13. Serum CCL19 and CCL21 were up-regulated during Rickettsia conorii infection. PMID: 24507453
14. CCL19 promoted monocyte adhesion to HUVEC cells. CCL19 rs2227302 was associated with coronary artery disease in a Chinese Han population. PMID: 24990231
15. CCL19 is an antimicrobial protein with bacteriocidal activity against E. coli. PMID: 12949249
16. CCL19 (rather than CCL21) may contribute to the accumulation of dendritic cells and macrophages in the inflamed lungs of patients with eosinophilic pneumonia. PMID: 24111618
17. CIP4 is expressed at abnormally high levels in CLL cells, where it is required for CCL19-induced chemotaxis. PMID: 23644527
18. Serum CCL19 measurement is a new hallmark of the B cell-mediated rheumatoid arthritis subtype and may predict clinical response to rituximab. PMID: 23740460
19. A high expression of CCL19 was a good prognostic factor of lung adenocarcinoma. PMID: 23922113
20. Our findings would suggest that CCL19 and CCL21 may not be associated with cervical lymph node metastasis or other clinical and microscopic factors in oral squamous cell carcinoma. PMID: 22976543
21. a novel signaling pathway that controls EDG-1 up-regulation following stimulation of T cells by CCR7 and CCL19. PMID: 22334704
22. involvement of CCL19 in AIDS patients with advanced immunodeficiency, potentially mediating both adaptive and maladaptive responses PMID: 22288592
23. These results suggest a new combinatorial guiding mechanism by CCL19 and CCL21 for the migration and trafficking of CCR7 expressing leukocytes. PMID: 21464944
24. increased expression of MIP-3alpha favors recruitment of immature DCs to the tumour bed, whereas de novo local expression of SLC and MIP-3beta induces accumulation of mature DCs at the tumour margin forming clusters with T-cells PMID: 20969772
25. Klebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cells. PMID: 20865789
26. Nuclear localization of four and a half LIM domains 2 (FHL2) transgene is lost in mature but not immature bone marrow-derived dendritic cells following stimulation with CCL19. PMID: 20592280
27. The CCL19 is known to be critically involved in lymphocyte and dendritic cell trafficking, CCL19-binding competition by CRAM might be involved in modulating these processes. PMID: 20002784
28. CC chemokine CCL19 attracts mature T cells out of the fetal thymus organ culture. PMID: 11869682
29. Desensitizing concentrations of CCL21 and CCL19 had no significant effects on T lymphocyte transendothelial migration. PMID: 11870628
30. located in high endothelial venules in an appropriate location to induce transendothelial migration of CLL cells into lymph nodes PMID: 11929789
31. Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR. (CCX-CKR) PMID: 11981810
32. migration to CCL19 and CCL21 is dependent on phospholipase C and intracellular calcium flux but not on phosphatidylinositol-3 kinase PMID: 14592837
33. CCL19 and CXCL12 have roles in chemotaxis of mantle cell lymphoma B cells PMID: 14871974
34. MIP-3beta was expressed in the human endometrium, but our results could not strongly support the hypothesis that MIP-3beta is a potential chemoattractant for endometrial NK cells. PMID: 15019823
35. The ccl19 migrated poorly towards the GFP UCB or normal (NL) BM CD34+ cells, p210 UCB and CML CD34+ cells. PMID: 15674360
36. By conditioning naive T cells into a motile dendritic cell-scanning state, CCL19 promotes antigen-independent responses and increases the probability of cognate histocompatibility complex (MHC)-peptide encounter. PMID: 16081805
37. Nitric oxide (NO) donor NOR4 provides a signal allowing LPS-stimulated DCs to migrate toward CCL19. PMID: 16249377
38. The maturation, in vitro migration and cytokine production of human DC after stimulation with live H. pylori is reported. PMID: 16500130
39. The CCL19,CCL21/CCR7 chemokine system is expressed in inflamed muscles of polymyositis and may be involved in the pathomechanism of polymyositis. PMID: 16887149
40. Despite sharing only 25% sequence identity with CCL21, the amino terminal hexapeptide of CCL19 is capable of performing an in vitro role similar to that of CCL21, resulting in G protein activation of the CCR7 receptor. PMID: 16904643
41. CXCL13 and CCL19 cooperatively induce significant resistance to TNF-alpha-mediated apoptosis in acute and chronic B cell leukemia CD23+CD5+ B cells, but not in the cells from cord blood. PMID: 17082584
42. Expression of the CCL19 gene is regulated by a combined action of several members of the NF-kappaB, IRF, and STAT family transcription factors. PMID: 17182562
43. The abundance of CD83+ plasmacytoid dendritic cells (DCs) in perivascular areas and the overexpression of CCL19 and CCL21 in perivascular cellular foci suggest plasmacytoid DCs are central to the muscle inflammation in juvenile dermatomyositis. PMID: 17469160
44. These findings suggest hitherto unknown roles of SMAD transcription factors and of CCL19 in the elicitation phase of allergic contact dermatitis. PMID: 17597826
45. CCL19 plus CXCL13 regulate interaction between B-ALL CD23+CD5+ B cells and CD8+ T cells by inducing activation of PEG10, in turn, resulting in IL-10 overexpression and impairment of tumor-specific cytotoxicity in syngeneic CD8+ T cells. PMID: 17709502
46. This study suggests that CCL19 plays a role in both the physiological immunosurveillance of the healthy CNS and the pathological maintenance of immune cells in the CNS of MS patients. PMID: 17825430
47. after HIV-1 infection of CCL19- or CCL21-treated CD4(+) T-cells, low-level HIV-1 production but high concentrations of integrated HIV-1 DNA, approaching that seen in mitogen-stimulated T-cell blasts, was observed PMID: 17881634
48. CCL19, CCL20 and CCL22 factors could play an additive role in the pathogenesis of the inflammatory process leading to bronchiolar fibro-obliteration in lung transplant patients PMID: 18047937
49. experiments performed to investigate the survival, adhesion, and metalloproteases secretion indicate that CXCL13 combined with CCL19 and CCL21 mainly affects the chemotaxis of Sezary syndrome cells PMID: 18757429
50. Complement C1q chemoattracts human dendritic cells and enhances migration of mature dendritic cells to CCL19 via activation of AKT and MAPK pathways.( PMID: 18838169
顯示更多

收起更多
亞細(xì)胞定位：

Secreted.
蛋白家族：

Intercrine beta (chemokine CC) family
組織特異性：

Expressed at high levels in the lymph nodes, thymus and appendix. Intermediate levels seen in colon and trachea, while low levels found in spleen, small intestine, lung, kidney and stomach.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 10617

OMIM: 602227

KEGG: hsa:6363

STRING: 9606.ENSP00000308815

UniGene: Hs.50002

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human